The conversation around Artificial Intelligence in healthcare has shifted. We are no longer asking “what can AI do?” but rather “how do we trust it, integrate it, and scale it?”

This shift was the heartbeat of the recent Frontiers Health Italy conference in Rome. It was a privilege to join the panel “Redefining Italian Healthcare with AI: New Strategies and the Role of Companies,” expertly moderated by Fulvio Fortini.

Alongside fellow panelists Carlo Salvioni and Vincenzo Giannattasio Dell’Isola, we moved beyond the hype to discuss the grounded realities of digital health. I want to extend a sincere thank you to EVERSANA and Roberto Ascione for curating a space where innovation is measured not just by technological novelty, but by its real-world integration into care.

The Core Challenge: Trust and Utility

The consensus from our discussion was clear: for AI to become a standard of care, it must be both trustworthy and useful.

Algorithms alone do not save lives; decisions do. For AI to support those decisions, it must be embedded within existing clinical workflows and patient journeys. It requires robust governance, clear explainability, and—crucially—human-in-the-loop design. We cannot simply automate care; we must augment the clinicians delivering it.

Generating Decision-Grade Evidence

During the panel, I emphasized a critical point that guides our strategy at Newel Health: AI and Real-World Data (RWD) must work together to generate decision-grade evidence.

Data is abundant, but insight is rare. The future of precision medicine lies in our ability to convert continuous, noisy signals from patient devices into validated digital endpoints. These endpoints allow us to:

• Intervene Earlier: Detecting subtle changes in a patient’s condition before they become acute events.
• Personalize Adherence: Understanding why a patient might be struggling with a therapy and adapting the support accordingly.
• Scale Precision: Deploying models that health systems can actually absorb and clinicians can supervise without burnout.

At Newel Health, we are applying this rigorous approach specifically in cardiovascular health, neuroscience, and pain management—areas where the gap between patient need and system capacity is widest.

Evolving Frameworks in Europe

Our approach is not happening in isolation; it mirrors the evolution of health technology assessment (HTA) frameworks across Europe and globally.

The direction from regulators and payers is becoming undeniable: evidence must be measurable, continuous, and embedded. The era of “launch and learn” is maturing into an era of “validate and integrate.” Solutions that cannot prove their value through rigorous data will struggle to find reimbursement pathways.

The Shared Goal

The path forward is collaborative. Our goal is to build solutions that earn the trust of the doctors who prescribe them and the patients who use them.

We are committed to continuing this work with partners who share that standard—building digital therapeutics that create lasting, durable value for the entire health ecosystem.